Pakistan’s first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies
The study revealed significant price escalations for most OADs, particularly those not enlisted on NEML, highlighting access challenges for diabetic patients and necessitating targeted policy reforms that address key market-related factors to ensure equitable access to OADs.
Authors
- Amna Saeed (ORCID: https://orcid.org/0000-0002-0284-0260)
- Sundus Shukar (ORCID: https://orcid.org/0000-0001-8078-165X)
- Zaheer‐Ud‐Din Babar (ORCID: https://orcid.org/0000-0003-1051-3240)
- Yu Fang
- Minghuan Jiang (ORCID: https://orcid.org/0000-0001-6536-5105)
- Nur Yasin (ORCID: https://orcid.org/0000-0001-5468-897X)
- Muhammad Majid Aziz (ORCID: https://orcid.org/0000-0002-6462-052X)
- Caijun Yang
- Haris Zahoor
- Muhammad Sunnan-Ud-Din
Institutions
- Bahauddin Zakariya University (PK)
- Riphah International University (PK)
- Qatar University (QA)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.3389/fphar.2025.1627735
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26